Abstract
The protein degradation start-up Epi- Biologics has launched with $50 million in series A funding. It is targeting cell-surface and extracellular proteins using antibody-based PROTACs, a platform the company calls EpiTAC. EpiBiologics says its atlas of degraders will lead to new treatments for cancer, as well as for immunology and neuro-related conditions. EpiBiologics is based on the work of cofounder Jim Wells, an antibody engineer at the University of California, San Francisco.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
